This Stock Of The Day Dines On Big Pharma Royalties; Up 56% In 2026

IBD Stock Of The Day

This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026

Licensing

02:09 PM ET 07/27/2026

Ligand Pharmaceuticals Ligand Pharmaceuticals LGND $ 296.24 $1.26 0.42% 31% IBD Stock Analysis Shares could rebound from 21-day exponential line, or possible form a flat base. If stock continues lower, watch for a rebound from the 50-day moving average. IBD Composite Rating 94/99 Industry Group Ranking 83/197 Emerging Pattern Pullback Pullback A stock may pull back after a breakout, often…

This Stock Of The Day Dines On Big Pharma Royalties; Up 56% In 2026

Other newsrooms on this story

Related reading

Biotech Dealmaker Dips Despite Beat And Raise

A biotech stock for investors scared to invest in the risky industry

IBD Stock Of The Day Eli Lilly Flashes Two Buy Signals

IBD Stock Of The Day Eyes Buy Point Amid Triple-Digit Growth

IBD Stock Of The Day Tops Buy Point. This Critical Report Lies Ahead.

How Roche's Comments Buoyed The IBD Stock Of The Day